Modeling Early Heterogeneous Rates of Progression in Boys with Duchenne Muscular Dystrophy.
Duchenne muscular dystrophy
cluster analysis
early age outcomes
heterogeneity in progression
longitudinal trajectories
Journal
Journal of neuromuscular diseases
ISSN: 2214-3602
Titre abrégé: J Neuromuscul Dis
Pays: Netherlands
ID NLM: 101649948
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
9
5
2023
pubmed:
23
2
2023
entrez:
22
2
2023
Statut:
ppublish
Résumé
Duchenne muscular dystrophy (DMD) exhibits substantial variability in rates of disease progression and response to treatment. This has hindered treatment development and complicated interpretation of drug effects in clinical trials. We hypothesized that a multivariate combination of early-age clinical outcome measurements can explain differential disease progression. Data on boys with DMD (ages 4-<10 years), both treated with steroidal anti-inflammatories and untreated, were obtained from CINRG Duchenne Natural History Study (n = 209) and vamorolone VBP15-002/003/LTE (n = 46) studies. Velocities from three timed function tests (TFTs; stand from supine, run/walk 10 meters, and climb 4 stairs) were simultaneously modeled in a longitudinal latent class analysis. Three classes of differentially progressing early age DMD motor trajectories were identified. Quicker decline/progression was associated with lower baseline TFT velocities, earlier loss of ability to finish a TFT, and lower predicted velocities. Earlier substantial steroid exposure was associated with greater TFT velocities while the moderate progression class was observed to have the largest difference in performance between boys treated early with steroids vs. not. Sample size calculations with the class showing the largest treatment response showed a large reduction in required sample size as compared to using summaries from all participants. Gene mutations were also investigated in post-hoc analyses, with mutations near the beginning of the DMD gene (Dp427 absent and Dp140/Dp71 present) found to be enriched in the slowest progressing class. This study provides insight into the variation in DMD progression through a latent class analysis. Our findings show class-related trajectories of motor outcomes and pharmacological response to corticosteroids, and suggest that enrichment strategies and/or subgroup analyses could be considered further in design of therapeutic interventions in DMD.
Sections du résumé
BACKGROUND
BACKGROUND
Duchenne muscular dystrophy (DMD) exhibits substantial variability in rates of disease progression and response to treatment. This has hindered treatment development and complicated interpretation of drug effects in clinical trials.
OBJECTIVE
OBJECTIVE
We hypothesized that a multivariate combination of early-age clinical outcome measurements can explain differential disease progression.
METHODS
METHODS
Data on boys with DMD (ages 4-<10 years), both treated with steroidal anti-inflammatories and untreated, were obtained from CINRG Duchenne Natural History Study (n = 209) and vamorolone VBP15-002/003/LTE (n = 46) studies. Velocities from three timed function tests (TFTs; stand from supine, run/walk 10 meters, and climb 4 stairs) were simultaneously modeled in a longitudinal latent class analysis.
RESULTS
RESULTS
Three classes of differentially progressing early age DMD motor trajectories were identified. Quicker decline/progression was associated with lower baseline TFT velocities, earlier loss of ability to finish a TFT, and lower predicted velocities. Earlier substantial steroid exposure was associated with greater TFT velocities while the moderate progression class was observed to have the largest difference in performance between boys treated early with steroids vs. not. Sample size calculations with the class showing the largest treatment response showed a large reduction in required sample size as compared to using summaries from all participants. Gene mutations were also investigated in post-hoc analyses, with mutations near the beginning of the DMD gene (Dp427 absent and Dp140/Dp71 present) found to be enriched in the slowest progressing class.
CONCLUSIONS
CONCLUSIONS
This study provides insight into the variation in DMD progression through a latent class analysis. Our findings show class-related trajectories of motor outcomes and pharmacological response to corticosteroids, and suggest that enrichment strategies and/or subgroup analyses could be considered further in design of therapeutic interventions in DMD.
Identifiants
pubmed: 36806514
pii: JND221527
doi: 10.3233/JND-221527
pmc: PMC10200136
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Anti-Inflammatory Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
349-364Subventions
Organisme : EPA
ID : EP-C-15-002
Pays : United States
Références
JAMA Neurol. 2022 Oct 1;79(10):1005-1014
pubmed: 36036925
Neurology. 2011 Jan 18;76(3):219-26
pubmed: 21178099
Am J Hum Genet. 2016 Nov 3;99(5):1163-1171
pubmed: 27745838
Lancet. 2018 Feb 3;391(10119):451-461
pubmed: 29174484
Neurology. 2019 Sep 24;93(13):e1312-e1323
pubmed: 31451516
J Cell Biol. 2014 Oct 13;207(1):139-58
pubmed: 25313409
Neurology. 2016 Feb 2;86(5):465-72
pubmed: 26833937
Nat Commun. 2017 Jan 31;8:14143
pubmed: 28139640
Neuromuscul Disord. 2016 Sep;26(9):576-83
pubmed: 27423700
PLoS One. 2019 Sep 3;14(9):e0221097
pubmed: 31479456
Sci Rep. 2019 Aug 21;9(1):12167
pubmed: 31434957
J Neuromuscul Dis. 2021;8(5):769-784
pubmed: 34120912
Hum Mol Genet. 2020 Aug 29;29(15):2481-2495
pubmed: 32592467
Lancet Neurol. 2003 Dec;2(12):731-40
pubmed: 14636778
Orphanet J Rare Dis. 2022 Jan 24;17(1):20
pubmed: 35073949
J Clin Med. 2019 May 10;8(5):
pubmed: 31083420
JAMA. 2022 Apr 19;327(15):1456-1468
pubmed: 35381069
J Neurol Neurosurg Psychiatry. 2015 Oct;86(10):1060-5
pubmed: 25476005
J Cachexia Sarcopenia Muscle. 2022 Apr;13(2):1360-1372
pubmed: 35083887
Neuromuscul Disord. 2018 Jan;28(1):4-15
pubmed: 29203355
Acta Myol. 2020 Dec 01;39(4):179-186
pubmed: 33458572
CPT Pharmacometrics Syst Pharmacol. 2022 Mar;11(3):318-332
pubmed: 34877803
Cochrane Database Syst Rev. 2016 May 05;(5):CD003725
pubmed: 27149418
Lancet. 2017 Sep 23;390(10101):1489-1498
pubmed: 28728956
PLoS One. 2009;4(2):e4347
pubmed: 19194511
Pharmacol Res. 2018 Oct;136:140-150
pubmed: 30219580
Muscle Nerve. 2019 Jun;59(6):650-657
pubmed: 30706490
Cell. 1987 Dec 24;51(6):919-28
pubmed: 3319190
J Comp Eff Res. 2020 Oct;9(14):973-984
pubmed: 32851872
PLoS Med. 2020 Sep 21;17(9):e1003222
pubmed: 32956407
JAMA Netw Open. 2022 Jan 4;5(1):e2144178
pubmed: 35076703
Eur J Paediatr Neurol. 2012 Mar;16(2):149-60
pubmed: 21920787
Ann Neurol. 2013 Apr;73(4):481-8
pubmed: 23440719